Specialists in sleep medicine are attuned to the tip of the sleep apnea iceberg: The middle-aged overweight man with a thick neck and a partner describing snoring and pauses in his breathing. This is the slam-dunk patient who creates so much job satisfaction, with a clear diagnosis and often a satisfying treatment response. That image has anchored sleep medicine for decades, and the stereotype has widely spilled over to clinicians who refer patients for sleep care.
It has also affected the perception of sleep apnea among patients themselves. Consequently, a woman with disrupted sleep will convince herself and everyone else in the (exam) room that she couldn’t possibly have sleep apnea. This is one reason why so many women never surface for sleep testing and why diagnosis is delayed until symptoms are severe or found to be refractory to multiple other treatment approaches, often for presumptive insomnia or mental health diagnoses.
Sleep apnea in women has been noticeably understudied, with early epidemiology drawn largely from men. Foundational sleep apnea studies enrolled mostly male patients, presumably with the idea that sleep apnea was uncommon in women and that hormonal fluctuations would confound data.
But diagnosis and treatment approaches built around that avatar will keep serving the people who fit it. Women who don’t snore loudly (or whose partners don’t notice) or who frame the problem as insomnia, stress, and exhaustion fall outside the stereotype. In sleep medicine clinics, the male-to-female ratio is as high as eight to one. Yet in community samples, up to 90% of women with OSA remain undiagnosed.
When Women Don’t Fit the Pattern
Women with OSA often have a subtle presentation. It is more likely to be a silent breathing disorder, either because there is little snoring or because no bed partner is there to notice it. When an arousal does occur, a single gasp is followed by the more noticeable problem of a prolonged middle-of-the-night awakening. Sleep disruption or long awakenings are what she reports, not the breathing problem.
Women describe daytime symptoms that are nonspecific, including fatigue, morning headaches, anxiety, low mood, and sleep that doesn’t feel restorative. A woman is far more likely to say she’s exhausted and self-diagnose insomnia rather than to say she stops breathing.
For example, let’s say a 42-year-old woman with increasingly disrupted sleep presents to her primary care provider wanting help for insomnia because as she puts it, she is “tired of being tired.” She denies snoring and waking up gasping for breath. She endures tossing and turning during the night, feeling like she “doesn’t ever get to deep sleep.” Several times a week she wakes up around 3 a.m. and often spends an hour trying to get back to sleep. As a result, she has trouble concentrating during the day (“brain fog”) and feels she is more irritable and anxious than usual.
When the chief complaint sounds like long periods of nighttime wakefulness, stress, or anxiety/depression, apnea rarely makes the differential, and the visit ends with sleep hygiene and stress reduction counseling or an antidepressant instead of a sleep study.
For those women who do have a sleep evaluation, the referring clinician commonly receives a study interpretation showing a normal or (technically) mild AHI and interprets it as reassuring. Worse yet, a woman who has “had a sleep study” may consider it “negative” or “mild” for years despite evolving and worsening sleep symptoms. Thus, the diagnosis is delayed and the damage accumulates.
We know that women commonly have respiratory events that cause sleep disruption rather than desaturation. Flow limitation fragment sleeps through respiratory effort-related arousals (RERAs), which raise the RDI but never register on the AHI. Further, sleep apnea may also concentrate in REM sleep, which means the AHI can be significantly diluted by normal breathing in NREM or a paucity of REM. This creates a significant discrepancy between the REM AHI and NREM AHI, with cardiometabolic consequences more heavily weighted on the REM AHI.
Sleep disruption is particularly evasive with home sleep apnea testing (HSAT), making airway-related sleep disruption difficult to detect or fully characterize. Poor sleep quality or elevated WASO during testing can further skew the study toward a deceptively underwhelming result. The report still hinges on the total AHI, such that a woman with genuine, symptomatic disease and an AHI of 8 is characterized as having mild sleep apnea. To the patient, this translates as “insignificant” or “not worth treating.” Women are adept at absorbing responsibility for symptoms disproportional to metrics. And often the referring clinician trusts the single number and moves on.
Catching a woman’s sleep apnea early is really about catching it at all, before the patient and their trusted primary care provider accumulate a stack of wrong explanations and failed treatments for downstream symptoms. Women may spend years attributing their nonspecific sleep/wake symptoms to hormones, thyroid disorders, menopause, or stress. And they get endorsement from clinicians involved in their care. Early diagnosis of sleep apnea has the power to collapse the years-to-decades window of misattribution. Further, at comparable severity, the cardiovascular and metabolic burden in women is at least as high, and by some measures worse, than men’s.
Untreated sleep-disordered breathing also contaminates the workup for almost everything adjacent: mood disorders, refractory insomnia, fatigue attributed to peri/menopause, metabolic and weight issues, dysrhythmia, and memory problems.
An early diagnosis does more than present a therapeutic trial of OSA treatment. It lets every downstream symptom be read against a unifying diagnosis of sleep apnea instead of through the noise of sleep fragmentation, sleep deprivation, sympathetic nervous system activation, and (eventually) hypoxemia.
Peri/Menopause Changes the Picture
For women, there is a steep inflection point where risk for sleep-disordered breathing increases: the perimenopause to menopause transition. Even sleep specialists may not recognize that a woman could be in perimenopause starting in her 40s (earlier for some) or experiencing an abrupt surgically-induced menopause. In perimenopause, progesterone trends downward first, followed by erratic estrogen fluctuations on a downward slope over several years. Progesterone helps maintain upper-airway muscle tone and acts as a respiratory stimulant. The drop in circulating hormones removes that protection. Estrogen plays a role in temperature and sleep stability, so variable hormone levels cause the internal balance to wobble. Women in midlife are increasingly vulnerable to the decreasing protection of progesterone and estrogen on nighttime breathing and sleep stability.
The trouble is that the resulting symptoms (fragmented sleep, fatigue, brain fog, mood changes, and weight gain) overlap with the perimenopause symptoms everyone already expects. A hot-flash narrative with prolonged awakenings can bury symptoms of disrupted breathing, even as they coexist. When we attribute everything to hormones, we stop confirming the airway, and a woman spends years being distracted with symptom management instead of addressing the root cause. Treating insomnia while missing the underlying breathing problem is one of the most common traps in the field. Chronic insomnia in a midlife woman should trigger a look at her airway before it earns a standing prescription for a hypnotic or antidepressant.
What Better Care Looks Like
Early diagnosis of a sleep-related breathing disorder is meaningful for a woman in midlife. The value is catching the problem while downstream effects are still modifiable. We already implement routine screening procedures to catch breast cancer, cervical cancer, and osteoporosis for women. Colonoscopies are done for both sexes. Screens for hypertension, diabetes, and dyslipidemia are also performed regularly. On the other hand, sleep apnea, which actually drives cardiometabolic pathology and is more common than breast cancer, is left to operate in the dark. Why not proactively and periodically screen for a preventable and treatable condition? I propose that symptomatic and at-risk women be screened for OSA in parallel with the mammogram model: home testing every one to two years.
A missed diagnosis or failing to recognize increasing risk related to life stage is not benign. It amounts to years of accumulating risk for hypertension, arrhythmia, insulin resistance, and daytime cognitive complaints, and the fatigue itself erodes work, mood, and quality of life long before anyone connects it to the airway. Early diagnosis empowers women to select treatment options proportional to their condition.
Sleep medicine physicians who interpret sleep studies for women in midlife have a chance to advocate for them. Whether attended or not, the interpretation should include actively scanning for flow limitation signals, highlighting REM-related events, and naming the sleep disruption that undercuts the accuracy of the test. The REM AHI, the supine AHI, the hypopnea burden, the arousal index, and the time spent in prolonged partial obstruction often tell a more accurate story than the global AHI, and these metrics are already sitting in the study waiting for your attention. Expert-guided clarity about these features in the interpretation report helps guide and educate the referring clinician to a more nuanced view. It also paves the way for a conversation about periodic retesting. A mild AHI shouldn’t end the conversation in a symptomatic woman. A sleep study showing an AHI less than 5 in a symptomatic woman can be called inconclusive. For female patients in midlife, evolving risk for sleep apnea may be anticipated over the following years.
None of this calls for new hardware. It calls for sensitivity to include peri/menopause assessment in the history, a lower threshold to test, use of the 3% hypopnea rule, reporting of RDI and RERAs, and a closer look at the raw data in front of us. It also means questioning male-normed cutoffs and thinking twice about a single night of home sleep testing in a woman, where night-to-night variability and REM-predominant disease can undercount real illness. It means treating the peri/menopause transition as a reason to screen again rather than a reason to stop looking. When clinical suspicion is high and a home sleep study comes back “negative,” consider re-framing as “inconclusive” and recommend scheduling a retest or an attended in-lab PSG. This isn’t overkill. It’s the appropriate next step.
Closing the Diagnostic Gap
The clinicians who see these women first, in primary care, obstetrics, and menopause practices, don’t need to become sleep specialists. Their job is to recognize sleep symptoms and refer to sleep specialists. From that perspective, the referral is the intervention, and there is an opportunity to educate in the interpretation report and hold a place for re-evaluation of new or worsening symptoms. Sleep clinics and testing programs can help by flagging symptomatic women with low indices for a closer look. In cases of “mild” sleep apnea, a therapeutic trial with PAP therapy or an oral appliance may reveal clinically significant improvements and serve to validate the woman’s experience.
The women we miss are not rare. They are sitting in exam rooms right now being told their labs are normal and their sleep study was unremarkable, while their fatigue, blood pressure, and metabolic health are eroding. Finding them earlier isn’t a technology problem. It’s a matter of expecting a different picture and interpreting what’s already in front of us with that perspective in mind.
This article originally appeared in SleepWorld Magazine Sept/Oct 2026 issue.
Audrey Wells, MD, is a women’s sleep health advocate and Menopause Society Certified Physician (MSCP) based in St. Paul, Minn., who is triple-board-certified in sleep medicine, obesity medicine, and pediatrics. She serves as chief medical officer (CMO) of SLIIIP.com (pronounced “sleep”), a comprehensive 50-state telemedicine practice that offers online video consultations, home sleep studies, and the full spectrum of treatments directed at optimizing sleep health for all.
References
- Bonsignore MR, Saaresranta T, Riha RL. Sex differences in obstructive sleep apnoea. Eur Respir Rev. 2019;28(154):190030.
- Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep. 1997;20(9):705-6.
- Franklin KA, Sahlin C, Stenlund H, Lindberg E. Sleep apnoea is a common occurrence in females. Eur Respir J. 2013;41(3):610-5.
- Quintana-Gallego E, Carmona-Bernal C, Capote F, et al. Gender differences in obstructive sleep apnea syndrome: A clinical study of 1166 patients. Respir Med. 2004;98(10):984-9.
- Shepertycky MR, Banno K, Kryger MH. Differences between men and women in the clinical presentation of patients diagnosed with obstructive sleep apnea syndrome. Sleep. 2005;28(3):309-314.
- Zhang B, Wing YK. Sex differences in insomnia: A meta-analysis. Sleep. 2006;29(1):85-93.
- Zeng LN, Zong QQ, Yang Y, et al. Gender difference in the prevalence of insomnia: A meta-analysis of observational studies. Front Psychiatry. 2020;11:577429.
- Won CHJ, Reid M, Sofer T, et al. Sex differences in obstructive sleep apnea phenotypes, the multi-ethnic study of atherosclerosis. Sleep. 2020;43(5):zsz274.
- Young T, Finn L, Austin D, Peterson A. Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med. 2003;167(9):1181-5.
- Huang T, Lin BM, Redline S, Curhan GC, Hu FB, Tworoger SS. Type of menopause, age at menopause, and risk of developing obstructive sleep apnea in postmenopausal women. Am J Epidemiol. 2018;187(7):1370-9.
